**Figure S9**

A

![Graph A](image1)

B

![Graph B](image2)

C

![Graph C](image3)
Figure S9. Baseline NAb responses against ChAd63. NAb titers against ChAd63 were assayed in the pre-immunization (day 0) serum of all volunteers. (A) Individual and median responses in Groups 1 and 2 are shown. The dotted lines indicate the level at which responses were classed as negative (titer <1:18) and high (titers >1:200). There was no significant difference between the volunteers enrolled into Group 1 or Group 2 (n = 8 per group, P = 0.18, Mann Whitney test). There were no significant correlations in either (B) Group 1 or (C) Group 2 between these low level pre-existing NAb titers and ChAd63 AMA1 immunogenicity as assessed by peak total summed AMA1 ELISPOT response at day 14 (blue) or anti-AMA1 (3D7) total IgG ELISA at day 28 (red). These were selected as the peak of the priming immune responses following ChAd63 AMA1 immunization. $r_s = 0.36, P = 0.39$ (ELISA) or $r_s = -0.53, P = 0.20$ (ELISPOT) in Group 1; and $r_s = 0.32, P = 0.43$ (ELISA) or $r_s = -0.02, P = 0.98$ (ELISPOT) in Group 2.